Literature DB >> 23798676

Degradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retina.

Jinok Choi1, Ann Lin, Eric Shrier, Lester F Lau, Maria B Grant, Brahim Chaqour.   

Abstract

CCN1 is a matricellular protein involved in normal vascular development and tissue repair. CCN1 exhibits cell- and context-dependent activities that are reflective of its tetramodular structure phylogenetically linked to four domains found in various matrix proteins. Here, we show that vitreal fluids from patients with proliferative diabetic retinopathy (PDR) were enriched with a two-module form of CCN1 comprising completely or partially the insulin-like growth factor-binding protein (IGFBP) and von Willebrand factor type C (vWC) domains. The two- and three-module forms comprising, in addition to IGFBP and vWC, the thrombospondin type 1 (TSP1) repeats are CCN1 degradome products by matrix metalloproteinase-2 and -14. The functional significance of CCN1 and its truncated variants was determined in the mouse model of oxygen-induced retinopathy, which simulates neovascular growth associated with PDR and assesses treatment outcomes. In this model, lentivirus-mediated expression of either CCN1 or the IGFBP-vWC-TSP1 form reduced ischemia-induced neovascularization, whereas ectopic expression of the IGFBP-vWC variant exacerbated pathological angiogenesis. The IGFBP-vWC form has potent proangiogenic properties promoting retinal endothelial cell growth, migration, and three-dimensional tubular structure formation, whereas the IGFBP-vWC-TSP1 variant suppressed cell growth and angiogenic gene expression. Both IGFBP-vWC and IGFBP-vWC-TSP1 forms exhibited predictable variations of their domain folding that enhanced their functional potential. These data provide new insights into the formation and activities of CCN1-truncated variants and raise the predictive value of the form containing completely or partially the IGFBP and vWC domains as a surrogate marker of CCN1 activity in PDR distinguishing pathological from physiological angiogenesis.

Entities:  

Keywords:  Angiogenesis; Cysteine-rich Protein 61 (CCN1); Endothelial Cell; Extracellular Matrix Proteins; Ischemia; Matricellular Protein; Matrix Metalloproteinase (MMP); Protein Degradation; Protein Domains; Retina

Mesh:

Substances:

Year:  2013        PMID: 23798676      PMCID: PMC3743481          DOI: 10.1074/jbc.M113.475418

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  60 in total

1.  The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain.

Authors:  Mikaël M Martino; Jeffrey A Hubbell
Journal:  FASEB J       Date:  2010-07-29       Impact factor: 5.191

2.  Differentiating vitreous proteomes in proliferative diabetic retinopathy using high-performance liquid chromatography coupled to tandem mass spectrometry.

Authors:  Hao Wang; Le Feng; Jianwen Hu; Chunlei Xie; Fang Wang
Journal:  Exp Eye Res       Date:  2012-12-28       Impact factor: 3.467

3.  Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue.

Authors:  R O Schlingemann; F J Rietveld; F Kwaspen; P C van de Kerkhof; R M de Waal; D J Ruiter
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

4.  SDF-1 is both necessary and sufficient to promote proliferative retinopathy.

Authors:  Jason M Butler; Steven M Guthrie; Mehmet Koc; Aqeela Afzal; Sergio Caballero; H Logan Brooks; Robert N Mames; Mark S Segal; Maria B Grant; Edward W Scott
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

5.  Stability of housekeeping gene expression in the rat retina during exposure to cyclic hyperoxia.

Authors:  Peter van Wijngaarden; Helen Mary Brereton; Douglas John Coster; Keryn Anne Williams
Journal:  Mol Vis       Date:  2007-08-29       Impact factor: 2.367

6.  Oxygen-induced retinopathy in the mouse.

Authors:  L E Smith; E Wesolowski; A McLellan; S K Kostyk; R D'Amato; R Sullivan; P A D'Amore
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-01       Impact factor: 4.799

7.  Pharmacoproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer cells: dynamics of membrane type 1 matrix metalloproteinase-mediated membrane protein shedding.

Authors:  Georgina S Butler; Richard A Dean; Eric M Tam; Christopher M Overall
Journal:  Mol Cell Biol       Date:  2008-05-27       Impact factor: 4.272

8.  Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis.

Authors:  Richard A Dean; Georgina S Butler; Yamina Hamma-Kourbali; Jean Delbé; David R Brigstock; José Courty; Christopher M Overall
Journal:  Mol Cell Biol       Date:  2007-10-01       Impact factor: 4.272

Review 9.  Functions and mechanisms of action of CCN matricellular proteins.

Authors:  Chih-Chiun Chen; Lester F Lau
Journal:  Int J Biochem Cell Biol       Date:  2008-08-15       Impact factor: 5.085

10.  Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix.

Authors:  Chandra Shekhar Boosani; Yakkanti A Sudhakar
Journal:  Pharmaceuticals (Basel)       Date:  2011-12
View more
  20 in total

1.  The matricellular protein CCN1 controls retinal angiogenesis by targeting VEGF, Src homology 2 domain phosphatase-1 and Notch signaling.

Authors:  Hemabindu Chintala; Izabela Krupska; Lulu Yan; Lester Lau; Maria Grant; Brahim Chaqour
Journal:  Development       Date:  2015-05-22       Impact factor: 6.868

2.  Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma.

Authors:  Afak Rasheed Salman Zaidi; Sadie Dresman; Charlotte Burt; Simon Rule; Lynn McCallum
Journal:  J Cell Commun Signal       Date:  2018-11-21       Impact factor: 5.782

Review 3.  Matricellular protein CCN1/CYR61: a new player in inflammation and leukocyte trafficking.

Authors:  Yalin Emre; Beat A Imhof
Journal:  Semin Immunopathol       Date:  2014-03-18       Impact factor: 9.623

4.  Regulating the regulators of angiogenesis by CCN1 and taking it up a Notch.

Authors:  Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2016-05-04       Impact factor: 5.782

Review 5.  The matricellular protein CCN1 in tissue injury repair.

Authors:  Ki-Hyun Kim; Jong Hoon Won; Naiyuan Cheng; Lester F Lau
Journal:  J Cell Commun Signal       Date:  2018-01-22       Impact factor: 5.782

Review 6.  Caught between a "Rho" and a hard place: are CCN1/CYR61 and CCN2/CTGF the arbiters of microvascular stiffness?

Authors:  Brahim Chaqour
Journal:  J Cell Commun Signal       Date:  2019-08-02       Impact factor: 5.782

7.  Molecular control of vascular development by the matricellular proteins CCN1 (Cyr61) and CCN2 (CTGF).

Authors:  Brahim Chaqour
Journal:  Trends Dev Biol       Date:  2013

8.  Single and Compound Knock-outs of MicroRNA (miRNA)-155 and Its Angiogenic Gene Target CCN1 in Mice Alter Vascular and Neovascular Growth in the Retina via Resident Microglia.

Authors:  Lulu Yan; Sangmi Lee; Douglas R Lazzaro; Jacob Aranda; Maria B Grant; Brahim Chaqour
Journal:  J Biol Chem       Date:  2015-08-04       Impact factor: 5.157

9.  LncRNA TUG1 Promotes Apoptosis, Invasion, and Angiogenesis of Retinal Endothelial Cells in Retinopathy of Prematurity via MiR-145-5p.

Authors:  Yuexia Wang; Yue Wang; Xue Wang; Yuan Ma; Zhaojin Li; Yu Di
Journal:  Front Med (Lausanne)       Date:  2022-04-04

10.  The mechanism of CCN1-enhanced retinal neovascularization in oxygen-induced retinopathy through PI3K/Akt-VEGF signaling pathway.

Authors:  Yu Di; Yiou Zhang; Hongwei Yang; Aiyuan Wang; Xiaolong Chen
Journal:  Drug Des Devel Ther       Date:  2015-04-30       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.